ECG recordings for patients entered into the RelieHF study

1667 20 6501 2 36206 document 6501 OBSOLETE-20200114_RELIEHF_Protocol_v4.pdf application/pdf 51bbb56162666293861df5ee2842e38b MD5 1366625 2024-06-27 14:12:31 https://researchdata.gla.ac.uk/1667/1/OBSOLETE-20200114_RELIEHF_Protocol_v4.pdf 1667 1 1 application/pdf Text en staffonly nsfs

OBSOLETE-20200114_RELIEHF_Protocol_v4.pdf

documentation 6502 2 36208 document 6502 OBSOLETE-20200227_RELIEHF_ECG_Management_SITES_Version.1.0.doc application/msword c5058781e971a02c81dc54f456575750 MD5 3693568 2024-06-27 14:12:35 https://researchdata.gla.ac.uk/1667/2/OBSOLETE-20200227_RELIEHF_ECG_Management_SITES_Version.1.0.doc 1667 2 2 application/msword Text en staffonly nsfs

OBSOLETE-20200227_RELIEHF_ECG_Management_SITES_Version.1.0.doc

documentation 6503 2 36210 document 6503 QPC19_RelieHF_Study.pdf application/pdf 77b70d1e4a9631c3ca1df6e48ff0587a MD5 1188905 2024-06-27 14:12:40 https://researchdata.gla.ac.uk/1667/3/QPC19_RelieHF_Study.pdf 1667 3 3 application/pdf Text en staffonly nsfs

QPC19_RelieHF_Study.pdf

documentation 6504 1 36215 document 6504 indexcodes.txt text/x-c 4c42621562a1394b69d219e4f5762058 MD5 5181 2024-06-27 14:14:06 https://researchdata.gla.ac.uk/1667/4/indexcodes.txt 1667 4 4 text/x-c other Generate index codes conversion from Text to indexcodes en staffonly

indexcodes.txt

http://eprints.org/relation/isVersionOf https://researchdata.gla.ac.uk/id/document/6502 http://eprints.org/relation/isVolatileVersionOf https://researchdata.gla.ac.uk/id/document/6502 http://eprints.org/relation/isIndexCodesVersionOf https://researchdata.gla.ac.uk/id/document/6502 archive 32961 disk0/00/00/16/67 2024-06-27 14:20:39 2025-09-12 08:55:15 2024-06-27 14:20:39 data_collection show Inglis Louise 8125 glaresearchdata:2024-06-26-1667 ECG recordings for patients entered into the RelieHF study 25201000 Funded by VIFOR Pharma Management AG, Flughofstrasse 61, Postfach, CH-8152 Glattbrugg, Switzerland, Tel: +41 58 851 80 00 The RelieHF study was looking at heart failure patients and using the study drug Patiromer, a potassium removing agent. The aim was to trial the potential for increasing dosages to improve worsening congestion, well-being, morbidity and mortality in patients with heart failure and hyperkalaemia, with a view to comparison with standard care. 2024-06-26 University of Glasgow 10.5525/gla.researchdata.1667 University of Glasgow FALSE English 2020-08-26 2023-05-01 2038-01-06 D-con For Confidential Destruction on 06 01 2038. 2025-09-12 LTW Louise Inglis confirmed retention date (destroy). email FALSE FALSE